Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Key Highlights
- ➤Mineralys (MLYS) appoints Kristine Peterson and Lonnel Coats to its Board of Directors
- ➤Appointments add commercial leadership ahead of potential lorundrostat approval and launch
- ➤Lorundrostat remains an investigational treatment for uncontrolled or resistant hypertension
Expert Statements
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics
“We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension.”
Kristine Peterson, Board member of Mineralys Therapeutics
“I am honored to join the Mineralys Board of Directors at such a pivotal time for the Company”
Kristine Peterson, Board member of Mineralys Therapeutics
“Having spent much of my career launching new medicines, including in cardiovascular disease, I appreciate the significant unmet need among patients whose hypertension is not controlled with currently available therapies.”
Kristine Peterson, Board member of Mineralys Therapeutics
“I look forward to working with the Company’s executive team and fellow Board members as Mineralys prepares for the potential commercial launch of lorundrostat.”
Lonnel Coats, Board member of Mineralys Therapeutics
“I am pleased to join the Mineralys Board of Directors”
Lonnel Coats, Board member of Mineralys Therapeutics
“Hypertension remains a leading driver of cardiovascular risk, and too many patients are unable to reach their blood pressure goals with currently available treatments.”
Lonnel Coats, Board member of Mineralys Therapeutics
“Lorundrostat has significant potential to offer a targeted treatment approach for hypertension driven by dysregulated aldosterone, and I look forward to contributing as the Company advances toward this next chapter.”
RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been appointed to the Company’s Board of Directors.
“We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension,” stated Jon Congleton, Chief Executive Officer of Mineralys. “As seasoned leaders who have each built and led commercial organizations, Kris and Lonnel bring deep experience launching and commercializing new therapies across multiple therapeutic areas, including cardiovascular and metabolic disease. We believe their track records of commercial execution, operational leadership and public company board service will make them valuable directors and resources as Mineralys transitions to a commercial-stage organization.”
Get started
Create a free account to read the full story.